PB2088: ABBV-383 IN COMBINATION WITH ANTI-CANCER REGIMENS IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: DOSE ESCALATION AND EXPANSION

• Cesar Rodriguez Valdes,
• Katja Weisel,
• Rachid Baz,
• Akshanth Polepally,
• Jeremy A. Ross,
• Ziyi Jin,
• Kristin D’amico,
• Orlando F. Bueno,
• Leanne Lash Fleming,
• Peter Voorhees

Affiliations

Cesar Rodriguez Valdes

1 Icahn School of Medicine at Mount Sinai, Medical Oncology and Hematology, New York, NY, United States

Katja Weisel

2 Department of oncology, Hematology, and Bone Marrow Transplantation with Section of pneumology, University Medical Center Hamburg-Eppendorf

Rachid Baz

3 Department of Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States

Akshanth Polepally

4 AbbVie Inc, South San Francisco, IL, United States

Jeremy A. Ross

5 AbbVie Inc, North Chicago, IL, United States

Ziyi Jin

6 AbbVie Inc, North Chicago, IL, United States

Kristin D’amico

6 AbbVie Inc, North Chicago, IL, United States

Orlando F. Bueno

6 AbbVie Inc, North Chicago, IL, United States

Leanne Lash Fleming

6 AbbVie Inc, North Chicago, IL, United States

Peter Voorhees

7 Levine Cancer Institute, Atrium Health/ Wake Forest Baptist, Charlotte, North Carolina, United States